282 related articles for article (PubMed ID: 27203208)
41. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses 5-hydroxytryptamine-induced pulmonary artery smooth muscle cell proliferation via JNK and ERK1/2 pathway.
Chen XY; Dun JN; Miao QF; Zhang YJ
Pharmacology; 2009; 83(2):67-79. PubMed ID: 19052484
[TBL] [Abstract][Full Text] [Related]
42. Twist promotes reprogramming of glucose metabolism in breast cancer cells through PI3K/AKT and p53 signaling pathways.
Yang L; Hou Y; Yuan J; Tang S; Zhang H; Zhu Q; Du YE; Zhou M; Wen S; Xu L; Tang X; Cui X; Liu M
Oncotarget; 2015 Sep; 6(28):25755-69. PubMed ID: 26342198
[TBL] [Abstract][Full Text] [Related]
43. A novel small-molecule MRCK inhibitor blocks cancer cell invasion.
Unbekandt M; Croft DR; Crighton D; Mezna M; McArthur D; McConnell P; Schüttelkopf AW; Belshaw S; Pannifer A; Sime M; Bower J; Drysdale M; Olson MF
Cell Commun Signal; 2014 Oct; 12():54. PubMed ID: 25288205
[TBL] [Abstract][Full Text] [Related]
44. Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling.
Zhong WB; Liang YC; Wang CY; Chang TC; Lee WS
Endocr Relat Cancer; 2005 Sep; 12(3):615-29. PubMed ID: 16172195
[TBL] [Abstract][Full Text] [Related]
45. Targeting the NRF-2/RHOA/ROCK signaling pathway with a novel aziridonin, YD0514, to suppress breast cancer progression and lung metastasis.
Li D; Wang H; Ding Y; Zhang Z; Zheng Z; Dong J; Kim H; Meng X; Zhou Q; Zhou J; Fang L; Shen Q
Cancer Lett; 2018 Jun; 424():97-108. PubMed ID: 29580806
[TBL] [Abstract][Full Text] [Related]
46. Dual Targeting of Mesenchymal and Amoeboid Motility Hinders Metastatic Behavior.
Jones BC; Kelley LC; Loskutov YV; Marinak KM; Kozyreva VK; Smolkin MB; Pugacheva EN
Mol Cancer Res; 2017 Jun; 15(6):670-682. PubMed ID: 28235899
[TBL] [Abstract][Full Text] [Related]
47. Cooperation of matrix metalloproteinases with the RhoA/Rho kinase and mitogen-activated protein kinase kinase-1/extracellular signal-regulated kinase signaling pathways is required for the sphingosine-1-phosphate-induced mobilization of marrow-derived stromal cells.
Meriane M; Duhamel S; Lejeune L; Galipeau J; Annabi B
Stem Cells; 2006 Nov; 24(11):2557-65. PubMed ID: 16931773
[TBL] [Abstract][Full Text] [Related]
48. Rho/Rho-associated kinase pathway in glaucoma (Review).
Wang J; Liu X; Zhong Y
Int J Oncol; 2013 Nov; 43(5):1357-67. PubMed ID: 24042317
[TBL] [Abstract][Full Text] [Related]
49. Multicellular spheroids from normal and neoplastic thyroid tissues as a suitable model to test the effects of multikinase inhibitors.
Cirello V; Vaira V; Grassi ES; Vezzoli V; Ricca D; Colombo C; Bosari S; Vicentini L; Persani L; Ferrero S; Fugazzola L
Oncotarget; 2017 Feb; 8(6):9752-9766. PubMed ID: 28039458
[TBL] [Abstract][Full Text] [Related]
50. Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis.
Vennin C; Chin VT; Warren SC; Lucas MC; Herrmann D; Magenau A; Melenec P; Walters SN; Del Monte-Nieto G; Conway JR; Nobis M; Allam AH; McCloy RA; Currey N; Pinese M; Boulghourjian A; Zaratzian A; Adam AA; Heu C; Nagrial AM; Chou A; Steinmann A; Drury A; Froio D; Giry-Laterriere M; Harris NL; Phan T; Jain R; Weninger W; McGhee EJ; Whan R; Johns AL; Samra JS; Chantrill L; Gill AJ; Kohonen-Corish M; Harvey RP; Biankin AV; ; Evans TR; Anderson KI; Grey ST; Ormandy CJ; Gallego-Ortega D; Wang Y; Samuel MS; Sansom OJ; Burgess A; Cox TR; Morton JP; Pajic M; Timpson P
Sci Transl Med; 2017 Apr; 9(384):. PubMed ID: 28381539
[TBL] [Abstract][Full Text] [Related]
51. NRF2 promotes breast cancer cell proliferation and metastasis by increasing RhoA/ROCK pathway signal transduction.
Zhang C; Wang HJ; Bao QC; Wang L; Guo TK; Chen WL; Xu LL; Zhou HS; Bian JL; Yang YR; Sun HP; Xu XL; You QD
Oncotarget; 2016 Nov; 7(45):73593-73606. PubMed ID: 27713154
[TBL] [Abstract][Full Text] [Related]
52. The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.
Knipe RS; Tager AM; Liao JK
Pharmacol Rev; 2015; 67(1):103-17. PubMed ID: 25395505
[TBL] [Abstract][Full Text] [Related]
53. 7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel ROCK inhibitor blocks cytoskeleton function and cell migration.
Tsai CC; Liu HF; Hsu KC; Yang JM; Chen C; Liu KK; Hsu TS; Chao JI
Biochem Pharmacol; 2011 Apr; 81(7):856-65. PubMed ID: 21276421
[TBL] [Abstract][Full Text] [Related]
54. RhoA/ROCK pathway mediates leptin-induced uPA expression to promote cell invasion in ovarian cancer cells.
Ghasemi A; Hashemy SI; Aghaei M; Panjehpour M
Cell Signal; 2017 Apr; 32():104-114. PubMed ID: 28104444
[TBL] [Abstract][Full Text] [Related]
55. RhoA/ROCK, cytoskeletal dynamics, and focal adhesion kinase are required for mechanical stretch-induced tenogenic differentiation of human mesenchymal stem cells.
Xu B; Song G; Ju Y; Li X; Song Y; Watanabe S
J Cell Physiol; 2012 Jun; 227(6):2722-9. PubMed ID: 21898412
[TBL] [Abstract][Full Text] [Related]
56. Extracellular heat shock protein 90α mediates HDM-induced bronchial epithelial barrier dysfunction by activating RhoA/MLC signaling.
Dong HM; Le YQ; Wang YH; Zhao HJ; Huang CW; Hu YH; Luo LS; Wan X; Wei YL; Chu ZQ; Li W; Cai SX
Respir Res; 2017 May; 18(1):111. PubMed ID: 28558721
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of RhoA but not ROCK induces chondrogenesis of chick limb mesenchymal cells.
Kim MJ; Kim S; Kim Y; Jin EJ; Sonn JK
Biochem Biophys Res Commun; 2012 Feb; 418(3):500-5. PubMed ID: 22281493
[TBL] [Abstract][Full Text] [Related]
58. Extracellular matrix 1 (ECM1) regulates the actin cytoskeletal architecture of aggressive breast cancer cells in part via S100A4 and Rho-family GTPases.
Gómez-Contreras P; Ramiro-Díaz JM; Sierra A; Stipp C; Domann FE; Weigel RJ; Lal G
Clin Exp Metastasis; 2017 Jan; 34(1):37-49. PubMed ID: 27770373
[TBL] [Abstract][Full Text] [Related]
59. Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton.
Fu XD; Giretti MS; Baldacci C; Garibaldi S; Flamini M; Sanchez AM; Gadducci A; Genazzani AR; Simoncini T
PLoS One; 2008 Jul; 3(7):e2790. PubMed ID: 18665217
[TBL] [Abstract][Full Text] [Related]
60. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
